New ALTG Study ILLUMINATE:
Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).
4th ALTG Preceptorship, Melbourne:
The response has been overwhelming, and we are now at full capacity. We would like to acknowledge our sponsors for this event:
Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cancer Australia, Pfizer Oncology, and Roche
